Learning about CAR-T Therapy with Dr. Noopur Raje image

Learning about CAR-T Therapy with Dr. Noopur Raje

May 12, 2022
06:30PM - 08:00PM EDT
Online Event
Overview

How familiar are you with CAR T Therapy? With two FDA approved CAR T therapies and another on the horizon, we are learning about this promising therapy and what it might mean for myeloma patients in terms of a cure.

Agenda
06:30 PM
Introductions
Audrey Burton-Bethkee
Audrey introduces the agenda of the event and featured speaker Dr. Noopur Raje.
06:35 PM
Member Spotlight
Ellen Reich
Ellen shares her myeloma journey, including her experience with CAR T.
06:45 PM
Presentation
Dr. Noopur Raje
Dr. Raje talks about CAR T Therapy, how it works and what it might mean for myeloma patients in terms of getting closer to a cure.
07:25 PM
Questions and Answers
Audience
Type your questions in the chat and we will answer them!
Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Noopur Raje, MD

Noopur Raje, MD

Noopur Raje, MD, is director of the Center for Multiple Myeloma at Massachusetts General Hospital. She is also Associate Professor of Medicine at Harvard Medical School. Her primary focus is treating patients with multiple myeloma and related plasma cell disorders. Dr. Raje leads a dedicated clinical team engaged in investigator-initiated, multi-center national and international clinical trials, all aimed at developing new promising therapies for multiple myeloma. Her laboratory efforts are focused on identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment for which targeting may result in improved therapeutic outcomes.